Pfizer is projected to increase 15.27% to $32.36 over the next 12 months, driven by a strong drug pipeline, raised revenue guidance, and a 6.19% dividend yield. Despite a recent $4.3 billion writedown and declines in COVID-related sales, Pfizer's new products and upcoming pivotal studies in oncology, obesity, and immunology support growth. The company’s shares have already gained over 18% year-to-date, and management forecasts steady revenue growth through 2033. Risks include generic competition and potential setbacks in obesity drug trials, but the overall outlook remains positive with a buy recommendation and 90% confidence.
Four stocks from Barron's Better Bets (BBB) list currently provide 'safer' dividends with yields from $1,000 invested that exceed their share prices, fitting the 'dogcatcher' ideal. Analyst forecasts suggest these top-ten BBB Dogs could achieve an av...
Pfizer is currently seen as significantly undervalued despite uncertainties from patent expirations and declining COVID revenues. The company maintains strong profitability with free cash flow margins expected above 30% through the decade, supporting...
